Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 3/20 | 1.00 |
| ▸ | MIF | P14174 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.78 |
| ▸ | NPC1 | O15118 | 5/20 | 0.78 |
| ▸ | RAB9A | P51151 | 5/20 | 0.78 |
| ▸ | MAPT | P10636 | 5/20 | 0.78 |
| ▸ | HPGD | P15428 | 5/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.78 |
| ▸ | TP53 | P04637 | 4/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.78 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | MAOA | P21397 | 2/20 | 0.78 |
| ▸ | MAOB | P27338 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.78 |
| ▸ | PKM | P14618 | 2/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29482686 | 1.00 | XDH (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29482679 | 1.00 | XDH (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29392289 | 1.00 | XDH (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29884186 | 0.91 | MIF (0.84) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| Daidzein SCHEMBL29374778 | 0.88 | KDM4E (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| Daidzein SCHEMBL21114371 | 0.88 | KDM4E (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| Daidzein SCHEMBL19814 | 0.88 | KDM4E (1.00) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8161550 | 0.87 | XDH (0.78) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL555129 | 0.87 | XDH (0.76) | XDHMIFKDM4EALDH1A1HSD17B10 | |
| SCHEMBL29929481 | 0.87 | XDH (0.76) | XDHMIFKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2603098-B1 | METHOD OF IMPROVING STABILITY OF SWEET ENHANCER AND COMPOSITION CONTAINING STABILIZED SWEET ENHANCER | FIRMENICH INCORPORATED (US) | 2025-08-06 | — | — | EP | claimed |
| US-12163004-B2 | Polymer composites | WARNER BABCOCK INSTITUTE FOR GREEN CHEMISTRY, LLC (US) | 2024-12-10 | — | — | US | claimed |
| CN-115975963-B | Method for synthesizing hydroxylated flavone compound by using escherichia coli P450 enzyme whole cell catalysis and application thereof | 江南大学 | 2023-10-03 | — | — | CN | claimed |
| CN-115975963-A | Method for synthesizing hydroxylated flavone compound by using escherichia coli P450 enzyme whole-cell catalysis and application | 江南大学 | 2023-04-18 | — | — | CN | claimed |
| CN-111574489-B | Synthetic method of 3',4', 7-trihydroxyisoflavone | 中国人民解放军联勤保障部队第九〇四医院 | 2022-04-29 | — | — | CN | claimed |
| US-10695283-B2 | Extract of Greyia radlkoferi and use thereof | UNIVERSITY OF PRETORIA (ZA) | 2020-06-30 | — | — | US | claimed |
| US-20190200602-A1 | Platelet Additive Solution Having a Beta-Galactosidase Inhibitor | VELICO MEDICAL, INC. (US) | 2019-07-04 | — | — | US | claimed |
| US-20190203175-A1 | Platelet Protection Solution Having a Beta-Galactosidase Inhibitor | VELICO MEDICAL, INC. (US) | 2019-07-04 | — | — | US | claimed |
| CN-104582713-B | Grignard family feijie extract and application thereof | 比勒陀利亚大学 | 2019-05-28 | — | — | CN | claimed |
| US-10271541-B2 | Platelet additive solution having a beta-galactosidase inhibitor | VELICO MEDICAL, INC (US) | 2019-04-30 | — | — | US | claimed |
| US-20120016019-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | US | claimed |
| US-20120016017-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | LEE GEE-HWOON (KR) | 2012-01-19 | — | — | US | claimed |
| US-20110224291-A1 | SKIN EXTERNAL COMPOSITION FOR INHIBITING EPIDERMAL HYPERPROLIFERATION AND ALLEVIATING INFLAMMATORY SKIN DISEASES CONTAINING ORTHODIHYDROXYISOFLAVONE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2011-09-15 | — | — | US | claimed |
| EP-2361089-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED -SYNUCLEIN FUNCTION | Parkinson's Institute (US) | 2011-08-31 | — | — | EP | claimed |
| EP-2349254-A2 | SKIN EXTERNAL COMPOSITION FOR INHIBITING EPIDERMAL HYPERPROLIFERATION AND ALLEVIATING INFLAMMATORY SKIN DISEASES CONTAINING ORTHO-DIHYDROXYISOFLAVONE DERIVATIVES | Amorepacific Corporation (KR) | 2011-08-03 | — | — | EP | claimed |
| US-20110033904-A1 | METHOD FOR PREPARING ORTHODIHYDROXYISOFLAVONES USING A BIOTRANSFORMATION SYSTEM | AMOREPACIFIC CORPORATION (KP) | 2011-02-10 | — | — | US | claimed |
| US-20100167286-A1 | Pluripotent cell lines and methods of use thereof | PARKINSON'S INSTITUTE (US) | 2010-07-01 | — | — | US | claimed |
| WO-2010058936-A2 | SKIN EXTERNAL COMPOSITION FOR INHIBITING EPIDERMAL HYPERPROLIFERATION AND ALLEVIATING INFLAMMATORY SKIN DISEASES CONTAINING ORTHO-DIHYDROXYISOFLAVONE DERIVATIVES | AMOREPACIFIC CORPORATION (KR) | 2010-05-27 | — | — | WO | claimed |
| WO-2010056413-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION | PARKINSON'S INSTITUTE (US) | 2010-05-20 | — | — | WO | claimed |
| WO-2010008486-A2 | PLURIPOTENT CELL LINES AND METHODS OF USE THEREOF | PARKINSONS INSTITUTE (US) | 2010-01-21 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120016019-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, H1-5, KRAS | XDH 2193/4885MIF 4579/4885KDM4E 4070/4885 |
| US-20120016017-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, WASHC5, ASAH1 | XDH 2755/4885MIF 4256/4885KDM4E 3250/4885 |
| US-20110224291-A1 | SKIN EXTERNAL COMPOSITION FOR INHIBITING EPIDERMAL HYPERPROLIFERATION AND ALLEVIATING INFLAMMATORY SKIN DISEASES CONTAINING ORTHODIHYDROXYISOFLAVONE DERIVATIVES | DKK1, FZD7, CTNND1 | XDH 2812/4885MIF 2317/4885KDM4E 2677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.